This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.

FTC submits post-trial brief in Otto Bock-Freedom Innovations case

( November 20, 2018, 22:21 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission has filed its post-trial brief and proposed findings of fact and conclusions of law in its challenge to the consummated Otto Bock HealthCare-Freedom Innovations deal. The FTC said it has proven the deal violates the antitrust laws and Otto Bock is attempting a "Hail Mary" of divesting a "limited set of hand-selected Freedom assets" rather than the full remedy of selling an ongoing Freedom business. The commission asked the agency's administrative law judge to issue its proposed order, "which would divest an ongoing Freedom business to a qualified buyer and fully restore competition in the U.S. [microprocessor knee] market."...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections